We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Live-Cell, Real-Time Monitoring of cAMP Kinetics with Promega GloSensor™ Technology

MADISON, WISCONSIN (April 3, 2008)

Promega Corporation announces the launch of a breakthrough cell-based biosensor technology, termed GloSensor™ Technology. The non-lytic, live-cell GloSensor cAMP Assay is the first application of the patent-pending technology, which features a genetically engineered form of firefly luciferase. The benefit to screeners and scientists alike will be more biologically relevant data captured directly from living cells.

cAMP is key signaling molecule for many G-protein coupled receptors. GloSensor cAMP Assay is the first bioluminescent cell-based biosensor for the direct, intracellular kinetic monitoring of cAMP, and ideally suited to HTS and uHTS application. "Early testers of the assay are telling us the ease and performance of the assay are phenomenal," says Neal Cosby, Promega Drug Screening Manager. "The kinetic profiling of cAMP afforded by this new technology will give scientists better insight into the biology of living cells under various treatments, such as agonist and antagonist screening." Because researchers simply combine cells, compounds and GloSensor cAMP Assay Reagent, the technology offers 'zero-step' assay potential.

Collaborator and company-sponsored presentations will be given at SBS 14th Annual Conference & Exhibition (April 6-10, 2008) in St. Louis. Promega scientists who developed the genetically engineered bioluminescent biosensors will be present at SBS to discuss the new technology with interested parties.

How the GloSensor cAMP Assay works. GloSensor cAMP Assay was created by fusion of a cAMP binding domain to the wild-type N- and C-termini of native firefly luciferase. New termini were created elsewhere in the luciferase fusion construct. In the absence of cAMP, the genetically modified luciferase containing the cAMP binding domain is in the inactive state (left side of image). Upon binding to cAMP, conformational changes in the cAMP binding domain likely determine the increased luminescence in the activated state that can be detected both in vitro and in living cells (right side of image). Both forms of luciferase are represented in the presence of luciferase substrate.

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.

For more information about a press release or about Promega in general, contact Promega Corporate Affairs at 1-608-274-4330 or via our contact page.

Choose your country


United States

Pacific Asia

Korea, Republic of


United Kingdom